



FORM PTO 449 U.S. Department of Commerce
Patent and Trademark Office

List of Documents Cited by Applicant

Application No.:	10/551,395
Filing Date:	September 29, 2005
First Named Inventor:	Callizot et al.
Group: 1614	To be assigned
Examiner: Royds	To be assigned
Attorney Docket No.:	1386/22

U.S. PATENT DOCUMENTS

Examiner Initial	Cite No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear
	1	6,482,822	11/19/2002	Bigg et al.	
	2	6,057,373	5/2/2000	Fogel, Barry	
	3	3,320,245	5/16/1967	Wolf et al.	
	4	3,320,249	5/16/1967	Bernstein et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number (country code, no., kind code (if known))	Publication Date	Name of Patentee or Applicant	Pages, columns, lines where relevant passages appear	T
	5	WO 2004/096231	11/11/2004	Neuro 3D		
	6	WO 99/07356	2/18/1999	Univ. of South Fl. Research Foundation		
	7	EP 0615749 A2	9/21/94	Virginia Commonwealth Univ.		
	8	WO 01/78709 A2	10/25/2001	Minerva Biotech. Corp.		
	9	WO 96/04915	2/22/1996	Albert Einstein College		
	10	WO 00/24390	5/4/2000	Univ. of British Colombia		
	11	WO 02/22611	3/22/2002	Vertex Pharm. Inc.		
	12	WO 02/083656	10/24/2002	Harnett et al.		
	13	WO 00/32175	6/8/2000	Pfizer Product Inc.		
	14	WO 01/92240	12/6/2001	Dal-Housie Univ.		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (06/13/2009)

/Leslie A. Royds/ (06/13/2009)

	15	WO 03/062232	7/31/2003	Harnett et al.		
	16	WO 03/062388	7/31/2003	Regents of Univ. of Ca.		

OTHER DOCUMENTS

Examiner Initials	Cite No.	Include Author (in CAPITAL LETTERS), Title, Journal, Date, Pertinent Pages, Etc.	T
	17	DAVIS ET AL. "Peripheral Diabetic Neuropathy Treated With Amitriptyline and Fluphenazine", <u>JAMA</u> , 238(21) : 2291-2292, Nov. 21, 1977.	
	18	MOSLEY ET AL. "Control of Diabetic Neuropathic Pain by Amitripty-Line (A) and Fluphenazine (F) in Mild Renal Failure" <u>J. of the Inter. Soc. of Nephrology</u> , 21(1) : 155, January 1982. ABSTRACT	
	19	GOMEZ-PEREZ, "Nortriptyline-Fluphenazine vs. Carbamazepine in the Symptomatic Treatment of Diabetic Neuropathy", <u>Archives of Med. Research</u> , 27(4) : 525-529, 1996.	
	20	GOMEZ-PEREZ ET AL., "Nortriptyline and Fluphenazine in the Symptomatic Treatment of diabetic Neuropathy. A Double-Blind Cross-Over Study", <u>Pain</u> , 23 : 395-400, 1985.	
	21	BATTLA ET AL., Clinical Trial of Amitriptyline and Fluphenazine in Diabetic Peripheral Neuropathy", <u>Southern Medical Journal</u> , 74(4) : 417-178, April 1981.	
	22	GOTTLIEH ET AL. "Depot Neuroleptics in the Treatment of Behavioral Disorders in Patients with Alzheimer's Disease", <u>JAGS</u> , 36 : 619-621, 1988.	
	23	VERMA ET AL. "N-Methyl-D-Aspartate Receptor Participation in Parkinson's Disease, a Neurodegenerative Disorder", <u>Annals of the N.Y. Acad of Sci.</u> , 765 : 327, 1995	
	24	HALE ET AL., "Low Dose Perphenazine and Levodopa/Carbidopa Therapy in a Patient with Parkinsonism and a Psychotic Illness", <u>J. of Nervous and Mental Health</u> , 168(5) : 312-314, 1980.	
	25	PERINI ET AL. "Trattamento con fluoperazina in un caso di allucinosis farmaco-indotta nel corso di terapia per morbo di Parkinson", <u>Gazzetta Medica Italiana</u> , 148(3) : 101-104, 1989.	

EXAMINER /Leslie A. Royds/ (06/13/2009) DATE CONSIDERED _____

*Examiner Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /LAR/ (06/13/2009)